The aim of DiaSurg 2 is to investigate the time-to-event of T2DM-induced morbidity and mortality after RYGB compared to medical treatment according to the most current clinical guidelines in patients with insulin-dependent T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.